Pharmacy Learning NetworkThyroid Tablets Recalled Due to Drug Superpotency

📋 Regulatory Action / Label Change

The FDA classified a voluntary recall of thyroid tablets, USP, 30 mg, as a Class I recall, the agency’s most serious recall designation. The action affects Lot 504950 (expiration September 2026) comprising 1,955 bottles distributed by Vitruvias Therapeutics. According to the recall notice, the product was found to be superpotent, creating the potential for serious adverse health consequences or death. Thyroid tablets are used in the treatment of hypothyroidism, thyroid cancer, and certain patients with goiter. The recall was initiated August 21, 2026, and received Class I classification on September 22, 2026.

Professional Impact

• Class I recalls represent the FDA’s highest-risk category, indicating a reasonable probability of serious adverse health consequences or death.
• The affected product is limited to Lot 504950, allowing targeted inventory review and quarantine procedures.
• Excess thyroid hormone exposure may increase the risk of clinically significant medication-related adverse events in susceptible patients.
• Community and health-system pharmacies may need to coordinate replacement therapy to prevent treatment interruptions.
• Pharmacy teams should review dispensing records to identify potentially affected patients and support recall communications.
• The event highlights the ongoing importance of manufacturer quality controls and pharmacy recall-management processes.

Action Items

• Identify and quarantine thyroid tablet inventory from Lot 504950.
• Remove affected product from active dispensing stock.
• Review dispensing records for potentially affected patients.
• Coordinate with prescribers and wholesalers to secure alternative product supply.
• Verify compliance with manufacturer and FDA recall instructions.